Range Low Price High Price Comment
30 days $1.23 $1.93 Wednesday, 1st May 2024 AKBA stock ended at $1.24. This is 1.59% less than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 4.84% from a day low at $1.24 to a day high of $1.30.
90 days $1.23 $2.47
52 weeks $0.780 $2.47

Historical Akebia Therapeutics prices

Date Open High Low Close Volume
Feb 02, 2016 $7.45 $7.45 $7.45 $7.45 267 500
Feb 01, 2016 $7.74 $7.74 $7.74 $7.74 387 200
Jan 29, 2016 $7.33 $7.33 $7.33 $7.33 1 464 900
Jan 28, 2016 $7.35 $7.35 $7.35 $7.35 451 100
Jan 27, 2016 $7.50 $7.50 $7.50 $7.50 504 100
Jan 26, 2016 $7.69 $7.69 $7.69 $7.69 517 200
Jan 25, 2016 $7.86 $7.86 $7.86 $7.86 628 400
Jan 22, 2016 $7.77 $7.77 $7.77 $7.77 824 500
Jan 21, 2016 $7.51 $7.51 $7.51 $7.51 725 600
Jan 20, 2016 $8.00 $8.00 $8.00 $8.00 696 600
Jan 19, 2016 $7.78 $7.78 $7.78 $7.78 820 100
Jan 15, 2016 $7.75 $7.75 $7.75 $7.75 994 000
Jan 14, 2016 $8.04 $8.04 $8.04 $8.04 569 000
Jan 13, 2016 $7.79 $7.79 $7.79 $7.79 755 200
Jan 12, 2016 $8.26 $8.26 $8.26 $8.26 632 300
Jan 11, 2016 $8.18 $8.18 $8.18 $8.18 1 134 000
Jan 08, 2016 $8.51 $8.51 $8.51 $8.51 1 855 400
Jan 07, 2016 $8.66 $8.66 $8.66 $8.66 5 041 500
Jan 06, 2016 $9.60 $9.60 $9.60 $9.60 1 383 700
Jan 05, 2016 $10.78 $10.78 $10.78 $10.78 1 351 700
Click to get the best stock tips daily for free!

About Akebia Therapeutics

Akebia Therapeutics Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra... AKBA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT